Symbiotec Pharmalab IPO
Updated 11 Sept 2026, 5:03 pm.
Minimum investment (Retail)
₹14,820
1 lot · 15 shares at the upper price band
Price band
₹988
Latest GMP
Not yet quoted
Est. listing price
—
Issue size
₹1757 Cr
GMP history
Each point is a recorded observation from the scheduled data sync.
GMP is an unofficial, unregulated grey-market estimate — not a prediction of listing performance.
Issue details
- Board
- Mainboard
- Price band
- ₹988
- Issue size
- ₹1757 Cr
- Lot size
- 15
- Opens
- 24 Aug 2026
- Closes
- 27 Aug 2026
- Allotment
- 28 Aug 2026
- Listing
- 1 Sept 2026
- Est. listing price
- —
- Listing price
- Awaited
- Listing gain
- Awaited
- Registrar
- MUFG Intime India Pvt.Ltd.
- Minimum investment
- ₹14,820 (1 lot · 15 shares)
- Face value
- ₹2 per share
- Issue type
- Bookbuilding IPO
- Sale type
- Fresh capital cum OFS
- Fresh issue
- ₹150 Cr
- Offer for sale
- ₹1,607 Cr
- Listing at
- BSE, NSE
- Refunds
- 31 Aug 2026
- Shares credited
- 31 Aug 2026
- Promoter holding
- 36.39% before · 33.28% after
- Lead managers
- JM Financial Ltd., Avendus Capital Pvt.Ltd., Motilal Oswal Investment Advisors Ltd., Nomura Financial Advisory & Securities (India) Pvt.Ltd.
Offer documents & links
Subscription by category
As of 27 Aug 2026, 1:24 pm.
Total subscription
52.60x
Full issue details
Details as published for this issue, read 11 Sept 2026, 4:59 am. Verify against the RHP before applying.
IPO Details
| IPO Date | 24 to 27 Aug, 2026 |
|---|---|
| Listed on | Tue, Sep 1, 2026 |
| Face Value | ₹ 2 per share |
| Price Band | ₹938 to ₹988 |
| Issue Price | ₹988 per share |
| Lot Size | 15 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹ 90.00 |
| Total Issue Size | 1,77,86,442 shares (agg. up to ₹ 1,757 Cr) |
|---|---|
| Fresh Issue | 15,21,261 shares (agg. up to ₹ 150 Cr) |
| Offer for Sale | 1,62,65,181 shares of ₹ 2 (agg. up to ₹ 1,607 Cr) |
| Share Holding Pre Issue | 6,27,34,851 shares |
| Share Holding Post Issue | 6,42,56,112 shares |
| BSE Script Code / NSE Symbol | 544889 / SYMBIOTEC |
| ISIN | INE899I01028 |
IPO Timetable
- IPO Open
- Mon, Aug 24, 2026
- IPO Close
- Thu, Aug 27, 2026
- Allotment
- Fri, Aug 28, 2026
- Refund
- Mon, Aug 31, 2026
- Credit of Shares
- Mon, Aug 31, 2026
- Listing
- Tue, Sep 1, 2026
Issue Reservation
| Investor Category | Shares | % of Net Issue | % of Total Issue | Max Allottees |
|---|---|---|---|---|
| QIB | 88,76,516 | 50.00% | 49.91% | NA |
| − Anchor Investor | 53,25,909 | — | 29.94% | NA |
| − QIB (Ex. Anchor) | 35,50,607 | — | 19.96% | NA |
| NII (HNI) | 26,62,956 | 15.00% | 14.97% | NA |
| − bNII > ₹10L | 17,75,304 | — | 9.98% | 8,453 |
| − sNII < ₹10L | 8,87,652 | — | 4.99% | 4,226 |
| Retail | 62,13,563 | 35.00% | 34.93% | 4,14,237 |
| Preferential Reservations | ||||
| Employee | 33,407 | — | 0.19% | NA |
| Total | 1,77,86,442 | 100.00% | 100.00% | — |
Symbiotec Pharmalab IPO comprises a total issue size of 1,77,86,442 shares. The net offer to the public is 1,77,53,035 shares, after excluding 33,407 shares under a preferential allotment. Of the Net offer 88,76,516 (50.00%) are allocated to QIB , 26,62,956 (15.00%) allocated to NII 62,13,563 (35.00%) allocated to RII .
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹1,92,660 |
| S-HNI (Min) | 14 | 210 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1005 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1020 | ₹10,07,760 |
Investors can bid for a minimum of 15 shares and in multiples thereof.
IPO Subscription Details
IPO Anchor Investors
| Bid Date | Fri, Aug 21, 2026 |
|---|---|
| Shares Offered | 53,25,909 |
| Anchor Portion (₹ Cr.) | 526.20 |
| Anchor lock-in period end date for 50% shares (30 Days) | Sat, Sep 26, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Wed, Nov 25, 2026 |
Symbiotec Pharmalab IPO raises ₹ 526.20 crore from anchor investors . Symbiotec Pharmalab IPO Anchor bid date is August 21, 2026 .
IPO Anchor Investors List
Investor Category Reservations
| Category | Limit | Cut-off |
|---|---|---|
| RII | Up to ₹2 Lakhs | Yes |
| sNII | ₹2 Lakhs – ₹10 Lakhs | No |
| bNII | Above ₹10 Lakhs | No |
| Employee (EMP) | Up to ₹5 Lakhs | Yes |
| Employee + RII/NII | Up to ₹5Lakhs (EMP) + RII/NII limits | Yes (EMP/RII) |
About Symbiotec Pharmalab Ltd.
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions.
With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations.
As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres.
Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards.
Competitive Strengths:
Global leadership in corticosteroid and steroidal hormone APIs.
Long-standing relationships with domestic and international customers.
Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record.
Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers.
Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.
Company Financials (Restated)
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.90 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| NET Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves and Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
| Amount in ₹ Crore |
Symbiotec Pharmalab Ltd.'s revenue increased by 15% and profit after tax (PAT) rose by 14% between the financial year ending with March 31, 2026 and March 31, 2025.
Recently Listed IPOs in Pharmaceuticals
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹68.17 |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹522.55 |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,200.80 |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,790.00 |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹201.78 |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹17.54 |
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹160.00 |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹36.75 |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹158.35 |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹282.00 |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹293.85 |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹208.75 |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹333.25 |
View More »
IPO Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | 112.50 |
| 2 | General Corporate Purposes | 29.53 |
| 3 | Issue Expenses | 105.02 |
| Total | 247.05 |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Key Performance Indicator (KPI)
| KPI | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| ROE | 11.19% | 12.66% |
| ROCE | 11.56% | 11.80% |
| RoNW | 9.48% | 11.79% |
| PAT Margin | 12.60% | 12.80% |
| EBITDA Margin | 26.59% | 27.26% |
| NAV | 184.69 | 150.17 |
| Price to Book Value | 5.35 | 6.58 |
Check IPO Peer Comparison here.
IPO Valuation
| Valuation Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 17.82 | 17.39 |
| P/E (x) | 55.44 | 56.81 |
| Market Cap at Offer Price | ₹6,094Cr. | ₹7,053.39 Cr |
Disclaimer
The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2026 available in RHP.
The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of March 31, 2026 available in RHP.
Shareholding Structure
| Category | Pre IPO | Post IPO |
|---|---|---|
| Promoter and Promoter Group | 36.39% | 33.28% |
| Public | 63.61% | 66.72% |
| Total | 100% | 100% |
Company Promoters: Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.
Offer For Sale - Selling Shareholders
| Name | Category | Estimated Amount (₹ cr.) |
|---|---|---|
| Satwani Holdings LLP | Promoter | 144.00 |
| Rosewood Investments | Other | 988.00 |
| India Business Excellence Fund III | Corporate | 475.00 |
| Total | — | 1,607.00 |
*Estimated Amount (₹ cr.) shown until the actual number of shares offered in OFS is entered.
Symbiotec Pharmalab IPO Recommendations
| Review By | Subscribe | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Brokers | 4 | 2 | 0 | 0 |
| Members | 0 | 0 | 0 | 0 |
IPO Subscription Status
| Category | Subscription (x) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB (Ex Anchor) | 181.20 | 35,50,608 | 64,33,59,195 |
| NII | 77.56 | 26,62,955 | 20,65,35,120 |
| bNII (> ₹10L) | 87.34 | 17,75,303 | 15,50,46,495 |
| sNII (< ₹10L) | 58.01 | 8,87,652 | 5,14,88,625 |
| Retail | 13.69 | 62,13,562 | 8,50,46,805 |
| Employee | 16.32 | 33,408 | 5,45,055 |
| Total | 75.08 | 1,24,60,533 | 93,54,86,175 |
The Symbiotec Pharmalab IPO is subscribed 75.08 times on August 27, 2026 6:54:54 PM (Day 4). The public issue subscribed 13.69 times in the retail category, 181.20 times in the QIB category, and 77.56 times in the NII category. Check Day by Day Subscription Details (Live Status)
Reload
Total Applications: 52,87,440
IPO Expenses
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Fees payable to the BRLMs and commissions (including underwriting commission, brokerage and selling commission, as applicable | 51.00 |
| 2 | Commission / processing fee for SCSBs, Bankers to the Offer and fee payable to the Sponsor Bank for Bids made by RIBs. Brokerage, underwriting commission and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs | 4.70 |
| 3 | Fees payable to Registrar to the Offer | 1.36 |
| 4 | Advertising and marketing expenses | 11.06 |
| 5 | Fee payable to auditors, consultants and market research firms | 7.41 |
| 6 | Listing fees, SEBI filing fees, upload fees, BSE and NSE processing fees, book building software fees and other regulatory expenses, Printing and distribution of stationery, Fees payable to legal counsel and Miscellaneous | 29.50 |
| Total | 105.02 |
Listing Day Trading Information
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹ 988.00 | ₹ 988.00 |
| Open | ₹ 978.20 | ₹ 988.00 |
| Low | ₹ 933.80 | ₹ 934.20 |
| High | ₹ 1,173.80 | ₹ 1,180.00 |
| Last Trade | ₹ 1,095.95 | ₹ 1,097.70 |
Check IPO Performance…
IPO Registrar
MUFG Intime India Pvt.Ltd.
022-49186000
symbiotecpharmalab.ipo@in.mpms.mufg.com
IPO Lead Manager(s)
JM Financial Ltd.
Avendus Capital Pvt.Ltd.
Motilal Oswal Investment Advisors Ltd.
Nomura Financial Advisory & Securities (India) Pvt.Ltd.
Contact Details
Symbiotec Pharmalab Ltd. Address
385/2,
Pigdamber, Rau,
Mhow,
Indore, Madhya Pradesh , 453331
+91 731 667 6405
secretarial@symbiotec.com
Symbiotec Pharmalab IPO in the news
Recent coverage in the financial press. Headlines are the publishers' own; verify details with the RHP.
Avendus Capital acted as book running lead manager to Symbiotec Pharmalab on its INR 700 cr pre-IPO and INR 1,757 cr IPO
Avendus · 4 Sept 2026
Symbiotec Pharmalab Share Price: Check Expected Listing Gain Based On Latest GMP
NDTV Profit · 1 Sept 2026
Symbiotec Pharmalab makes muted debut despite 19% GMP premium expectations
CNBC TV18 · 1 Sept 2026
Symbiotec Pharmalab makes tepid market debut, lists at par with IPO price
Business Standard · 1 Sept 2026
Symbiotec Pharmalab shares make flat debut on exchanges; should you buy, sell or hold?
Moneycontrol.com · 1 Sept 2026
Symbiotec Pharmalab IPO listing: Shares list at a 1% discount on BSE; should investors buy more, book profits, or hold?
Livemint · 1 Sept 2026
